NDAORALTABLETPriority Review
Approved
Mar 2004
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
3
Intelligence
7/8 — Comprehensive
Priority Review
SENSIPAR (cinacalcet hydrochloride) by Amgen is calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of pth synthesis and secretion. Approved for secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies ( )], hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies ( )], hypercalcemia in adult patients with primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels and 1 more indications. First approved in 2004.
Mechanism of Action
calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, is a calcimimetic agent that directly lowers PTH levels by increasing the sensitivity of the calcium-sensing…
Worked on SENSIPAR at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.